Aaron T. Wild

Aaron T. Wild

Auto-generated profile, based on publicly available information

Aaron T. Wild

Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2013 in Journal of Radiation Oncology
Verified
Journal Article
Open access
PDF file
ADAvani S. Dholakia
Avani S. Dholakia
AHAmy Hacker-Prietz
Amy Hacker-Prietz
AWAaron T. Wild
Aaron T. Wild
SRSiva P. Raman
Siva P. Raman
LWLaura D. Wood
Laura D. Wood
JHJoseph M. Herman
Joseph M. Herman
Objective Neoadjuvant therapy increases rates of margin-negative resection of borderline resectable pancreatic ductal adenocarcinoma (BL-PDAC). Criteria for BL-PDAC resection following neoadjuvant chemotherapy and radiation therapy (NCRT) have not been clearly defined. Methods Fifty consecutive patients with BL-PDAC who received NCRT from 2007 to 2012 were identified. Computed tomography (CT) scans pre- and post-treatment were centrally reviewed. Results Twenty-nine patients (58 %) underwent resection following NCRT, while 21 (42 %) remained unresected. Patients selected for and successfully undergoing resection were more likely to have better performance status and absence of the following features on pre- and post-treatment CT: superior mesenteric vein/portal vein encasement, superior mesenteric artery involvement, tumor involvement of two or more vessels, and questionable/overt metastases (all p < 0.05). Tumor volume and degree of tumor–vessel involvement did not significantly change in both groups after NCRT (all p > 0.05). The median overall survival was 22.9 months in resected versus 13.0 months in unresected patients (p < 0.001). Of patients undergoing resection, 93 % were margin-negative, 72 % were node-negative, and 54 % demonstrated moderate pathologic response to NCRT. Conclusion Apparent radiographic extent of vascular involvement does not change significantly after NCRT. Patients without metastatic disease should be chosen for surgical exploration based on adequate performance status and lack of disease progression.

1 April 2013 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
NGNishant Gandhi
Nishant Gandhi
AWAaron T. Wild
Aaron T. Wild
SCSivarajan T. Chettiar
Sivarajan T. Chettiar
KAKhaled Aziz
Khaled Aziz
YKYoshinori Kato
Yoshinori Kato
PTPhuoc Tran
Phuoc Tran
Outcomes for poor-risk localized prostate cancers treated with radiation are still insufficient. Targeting the “non-oncogene” addiction or stress response machinery is an appealing strategy for cancer therapeutics. Heat-shock-protein-90 (Hsp90), an integral member of this machinery, is a molecular chaperone required for energy-driven stabilization and selective degradation of misfolded “client” proteins, that is commonly overexpressed in tumor cells. Hsp90 client proteins include critical components of pathways implicated in prostate cancer cell survival and radioresistance, such as androgen receptor signaling and the PI3K-Akt-mTOR pathway. We examined the effects of a novel non-geldanamycin Hsp90 inhibitor, AUY922, combined with radiation (RT) on two prostate cancer cell lines, Myc-CaP and PC3, using in vitro assays for clonogenic survival, apoptosis, cell cycle distribution, γ-H2AX foci kinetics and client protein expression in pathways important for prostate cancer survival and radioresistance. We then evaluated tumor growth delay and effects of the combined treatment (RT-AUY922) on the PI3K-Akt-mTOR and AR pathways in a hind-flank tumor graft model. We observed that AUY922 caused supra-additive radiosensitization in both cell lines at low nanomolar doses with enhancement ratios between 1.4–1.7 (p < 0.01). RT-AUY922 increased apoptotic cell death compared with either therapy alone, induced G2-M arrest and produced marked changes in client protein expression. These results were confirmed in vivo, where RT-AUY922 combination therapy produced supra-additive tumor growth delay compared with either therapy by itself in Myc-CaP and PC3 tumor grafts (both p < 0.0001). Our data suggest that combined RT-AUY922 therapy exhibits promising activity against prostate cancer cells, which should be investigated in clinical studies.

Verified
Journal Article
Open access
PDF file
SASara Alcorn
Sara Alcorn
AWAmanda J. Walker
Amanda J. Walker
NGNishant Gandhi
Nishant Gandhi
ANAmol Narang
Amol Narang
AWAaron T. Wild
Aaron T. Wild
PTPhuoc Tran
Phuoc Tran
As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.

28 July 2015
Verified
Journal Article
Closed access
SEShereef M Elnahal
Shereef M Elnahal
SEShereef M Elnhal
Shereef M Elnhal
SMShalini Moningi
Shalini Moningi
AWAaron T Wild
Aaron T Wild
ADAvani S Dholakia
Avani S Dholakia
JHJoseph M Herman
Joseph M Herman

1 September 2013 in Current Problems in Cancer
Verified
Journal Article
Closed access
AWAaron T. Wild
Aaron T. Wild
KFKatherine Y. Fan
Katherine Y. Fan
JHJoseph M. Herman
Joseph M. Herman

1 April 2012 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
KKKatherine Kim
Katherine Kim
ETErik J. Tryggestad
Erik J. Tryggestad
AWAaron T. Wild
Aaron T. Wild
MZMark A. Ziegler
Mark A. Ziegler
ESEun J. Shin
Eun J. Shin
MKMouen Khashab
Mouen Khashab